In-vitro and in-vivo evaluation of HCV polymerase inhibitors as potential drug candidates for treatment of chronic hepatitis C infection.

被引：0
|
作者：
Dagan, S
Ilan, E
Aviel, S
Nussbaum, O
Arazi, E
Ben-Moshe, O
Slama, D
Tzionas, I
Shoshany, Y
Lee, SW
Han, JJ
Park, SJ
Lee, GH
Park, EY
Shin, JC
Suh, JW
Ji, M
Kim, JW
机构：
[1] XTL Biopharmaceut Ltd, Rehovot, Israel
[2] B&C Biopharm, Kyungki, South Korea
[3] Myong Ji Univ, Yongin, Gyunggido, South Korea
来源：
HEPATOLOGY | 2003年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
135
引用
收藏
页码：221A / 221A
页数：1
相关论文
共 50 条
  • [31] Platelet count as an indirect marker of histological severity in chronic hepatitis C virus (HCV) infection.
    Figueiredo-Mendes, CG
    Al Mattos, C
    Figueiredo, VM
    Pacheco, MS
    Perez, RM
    Silva, AE
    Ferraz, ML
    HEPATOLOGY, 2000, 32 (04) : 550A - 550A
  • [32] Loss of HCV RNA in female patients after delivery with chronic hepatitis C virus infection.
    Hattori, Y
    Orito, E
    Ohno, T
    Kato, H
    Sugauchi, F
    Suzuki, S
    Hasegawa, I
    Sakurai, M
    Ueda, R
    Mizokami, M
    HEPATOLOGY, 2001, 34 (04) : 564A - 564A
  • [33] EVALUATION IN-VIVO AND IN-VITRO OF AMOXYCILLIN IN TREATMENT OF URINARY INFECTIONS IN OBSTETRICS AND GYNECOLOGY
    TAN, P
    VANDEPITTE, J
    SPAEPEN, J
    CLAERHOUT, J
    CARTRYSSE, U
    Vanassch, A
    CHEMOTHERAPY, 1973, 18 : 69 - 80
  • [34] Predictors of Treatment for Hepatitis C Virus (HCV) Infection in Drug Users
    Reed, Carrie
    Stuver, Sherri O.
    Tumilty, Sheila
    Nunes, David
    Murray, Jessica E.
    Graham, Camilla S.
    Koziel, Margaret James
    Craven, Donald E.
    Skolnik, Paul R.
    Horsburgh, C. Robert, Jr.
    SUBSTANCE ABUSE, 2008, 29 (01) : 5 - 15
  • [35] NS3 serine protease inhibitors as potential antiviral agents for the treatment of hepatitis C virus infection.
    Llinàs-Brunet, M
    Bailey, M
    Cameron, D
    Ferland, JM
    Ghiro, E
    Gorys, V
    Goudreau, N
    Halmos, T
    Narl, H
    Poirier, M
    Rancourt, J
    Tsantrizos, Y
    Lamarre, D
    ANTIVIRAL RESEARCH, 2002, 53 (03) : A73 - A73
  • [36] Rivaroxaban-loaded SLNs with treatment potential of deep vein thrombosis: in-vitro, in-vivo, and toxicity evaluation
    Luo, Xuemei
    Saleem, Aiman
    Shafique, Uswa
    Sarwar, Sadia
    Ullah, Kalim
    Imran, Muhammad
    Zeb, Alam
    Din, Fakhar ud
    PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2023, 28 (07) : 625 - 637
  • [37] Evaluation of a model of adjustment in a group of Irish women with an iatrogenic hepatitis C virus (HCV) infection.
    Coughlan, BM
    Sheehan, J
    Carr, A
    Bunting, B
    Crowe, J
    HEPATOLOGY, 2001, 34 (04) : 688A - 688A
  • [38] Treatment of chronic hepatitis C virus infection. A study of best predictors for response
    Ospina Vanegas, Nataly
    Rodriguez San Roman, Jose Luis
    Hernandez Febles, Melisa
    Garcia Sanchez, Claudio
    Martin Suarez, Jose Maria
    Redondo Martinez, Elena
    Olivia Hernandez, Leonor
    Pena Lopez, Maria Jose
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2011, 24 (04) : 198 - 203
  • [39] Treatment with etanercept in 6 patients with rheumatologic disesase and chronic hepatitis C infection.
    Ceribelli, A.
    Cavazzana, I.
    Cattaneo, R.
    Franceschini, F.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2008, 26 (01) : S87 - S88
  • [40] Controlled release floating drug delivery system for proton pump inhibitors lansoprazole: In-vitro, In-vivo floating and pharmacokinetic evaluation
    Murad, Shiza
    Mudassir, Jahanzeb
    Faiz, Sumaira
    Zahra, Andleeb
    Usman, Faisal
    Farhan, Muhammad
    Arshad, Muhammad Sohail
    Abbas, Nasir
    Hussain, Amjad
    Baig, Mirza Muhammad Faran Ashraf
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 35 (01) : 195 - 201
12345